Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment

PURPOSE: Novel targeted and immunotherapies have improved outcomes in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but toxicities limit widespread use. The selective Bruton tyrosine kinase (BTK) inhibitor acalabrutinib has activity in patients with R/R DLBCL but durable responses...

Descripción completa

Detalles Bibliográficos
Autores principales: Roschewski, Mark, Patel, Manish R., Reagan, Patrick M., Saba, Nakhle S., Collins, Graham P., Arkenau, Hendrik-Tobias, de Vos, Sven, Nuttall, Barrett, Acar, Melih, Burke, Kathleen, White, Rafael D., Udriste, Maria, Sharma, Shringi, Dougherty, Brian, Stetson, Daniel, Jenkins, David, Mortlock, Andrew, Forcina, Alessandra, Munugalavadla, Veerendra, Flinn, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472096/
https://www.ncbi.nlm.nih.gov/pubmed/37364001
http://dx.doi.org/10.1158/1078-0432.CCR-22-2483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472096/
https://www.ncbi.nlm.nih.gov/pubmed/37364001
http://dx.doi.org/10.1158/1078-0432.CCR-22-2483

Ejemplares similares